deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03315754

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.

Sponsor: Steba Biotech S.A.

Conditions Localized Prostate Cancer
Interventions TOOKAD Soluble 4 mg/kg
Updated 13 times since 2017 Last updated: Nov 28, 2024 Started: Oct 2, 2017 Primary completion: Nov 2, 2020 Completion: Feb 2, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Localized Prostate Cancer, this trial is ongoing. The trial is conducted by Steba Biotech S.A. and has accumulated 13 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Jan 2020 · 11 months · monthly snapshot~Jan 2020 – ~Dec 2020 · 11 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2022 · 14 months · monthly snapshot~Jun 2022 – ~Sep 2023 · 15 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – present · 18 months · monthly snapshot

Change History

13 versions recorded

  1. Jan 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 8 earlier versions

  1. Jun 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Feb 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  8. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Steba Biotech S.A.
Data source: Steba Biotech S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations